Get the app
US › Healthcare

Kazia Therapeutics Ltd ADR (KZIA)

US · Healthcare · Biotechnology

$10.86+6.47%
Last close · 2026-09-17

Latest quarter · ended 2025-12-31

Net profit
$-12.3M
EPS
$-7.64
EPS estimate
$-221.00

EPS came in at -7.64 against a street estimate of -221.00 — a beat of 96.5%.

Key statistics

Market cap
$118.4M
Forward P/E
12.8
P/B
5.20
Book value
$2.94
EPS (TTM)
$-7.62
52-week high
$17.40
52-week low
$4.86
50-day MA
$13.09
200-day MA
$10.63
Beta
2.15

Analyst view

Analysts rate Kazia Therapeutics Ltd ADR a buy (1 buy, 0 hold, 0 sell out of 1) with an average price target of $29.37.

Shareholding

Insiders
15.42%
Institutions
28.50%

Largest institutional holders

FundStake
Bleichroeder LP3.50%
Stonepine Capital Management Llc3.02%
Point72 Asset Management, L.P.1.75%
Balyasny Asset Management LLC1.69%
F.L.Putnam Investment Management1.25%
Millennium Management LLC0.89%
Dauntless Investment Group, LLC0.70%
Westside Investment Management, Inc.0.44%

See the full picture

Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Kazia Therapeutics Ltd ADR — free to start.

Google PlayApp Store

Other Healthcare companies

Eli Lilly and CompanyJohnson & JohnsonAbbVie IncMerck & Company IncUnitedHealth Group IncorporatedNovartis AG ADRAstraZeneca PLCThermo Fisher Scientific IncAmgen IncNovo Nordisk A/SGilead Sciences IncAbbott Laboratories

Data updated 2026-09-18.